evipedia.ai
← Back

Topical Naringenin for Hair Regrowth

Evidence Review created on 09/25/2026 using AI4L / Opus 5.5

Also known as: Naringenin, NAR, Naringetol, Salipurol, 4′,5,7-Trihydroxyflavanone, (2S)-Naringenin

Motivation

Naringenin is a natural plant compound that gives grapefruit and oranges part of their bitter taste. Applied directly to the scalp as a liquid or serum, it is being explored as a low-cost, non-hormonal way to support hair regrowth. Its main proposed action is to strengthen the growth signals of hair-forming cells while shielding them from chemical wear and irritation.

Interest has grown because thinning hair is common with age in both men and women, and many people find the standard medicines either too modest in effect or too burdened with side effects. Laboratory work on human scalp cells and a small animal study reported more hair growth with naringenin, and a closely related citrus compound produced similar findings in animals. For people who view hair density as one visible marker of healthy aging, an add-on that works differently from standard medicines is of interest.

This review examines how scalp-applied naringenin may work, how strong the evidence for hair regrowth is, what risks and interactions are known, and how it compares with established treatments. It also covers practical routines, product quality, and ways to track results.

Benefits - Risks - Protocol - Conclusion

Expert commentary and primary research on topical naringenin and on hair-regrowth approaches that share its proposed mechanism.

Content from Peter Attia, Chris Kresser, and Lifespan.io is not included. None of them discusses naringenin for hair or topical flavonoids; Lifespan.io covers naringenin only as a compound against cell aging and brain aging. Attia’s hair-loss guide (AMA #63) is members-only and covers conventional treatments. Lifespan.io’s hair-loss coverage is about an unrelated follicle stem-cell drug. Kresser’s hair articles deal with nutritional and hormonal causes, not topical agents.

Grokipedia

Naringenin

A broad overview of naringenin’s chemistry, food sources, absorption, metabolism, and safety profile; useful background, though it does not address hair or scalp application.

Examine

Naringenin benefits, dosage, and side effects

Summarizes oral naringenin research as mostly animal and cell-based, covering antioxidant, anti-inflammatory, and heart-related effects; it contains no hair or topical data but frames the thin human evidence base.

ConsumerLab

No ConsumerLab article on naringenin was found.

Systematic Reviews

Systematic reviews on polyphenols and botanicals for hair loss, on the conventional treatments naringenin would compete with, and on the main vehicle-related risk; none evaluates naringenin itself.

No systematic review or meta-analysis addresses the efficacy or safety of naringenin applied to the scalp; both the claimed effect and the principal risk are represented only through class-level and vehicle-level reviews.

Mechanism of Action

Naringenin is a flavanone (a citrus subgroup of plant flavonoids). Proposed hair effects, from cell and rodent data:

  • Growth-signal support: in cultured human dermal papilla cells and keratinocytes it increased cell division and release of VEGF (vascular endothelial growth factor, a blood-vessel growth signal) (Madaan et al., 2017); in mice it raised skin VEGF and follicle counts (Khayoon et al., 2023).
  • Antioxidant and anti-inflammatory action: it preserved Nrf2 (a switch for the cell’s antioxidant defenses) expression and lowered cytokines (inflammatory signaling proteins) in irradiated mouse skin (Martinez et al., 2016).
  • Pigment-cell activation: it switched on Wnt/β-catenin signaling (a pathway driving follicle growth and pigment production) in pigment cells (Huang et al., 2011).

A competing mechanism argues against benefit: naringenin blocked VEGF-driven blood-vessel growth in endothelial cells (cells lining blood vessels) and mice (Pafumi et al., 2017), a measure of vessel response, not VEGF levels. It also lacks antiandrogen (male-hormone-blocking) activity (Zierau et al., 2003), so it does not counter DHT (dihydrotestosterone, the hormone driving pattern hair loss).

Pharmacology:

  • Half-life: 2.65–3.0 hours after oral dosing (Rebello et al., 2020).
  • Selectivity: low; it acts on many targets.
  • Tissue distribution: topically it stays mostly in the epidermis (outer skin layer), but a damaged barrier raises penetration 13-fold (Alalaiwe et al., 2020).
  • Metabolism: cleared mainly by glucuronidation via UGT enzymes (which tag compounds for excretion) and sulfation; it weakly, competitively inhibits CYP3A4 (a liver enzyme that breaks down many drugs) (Bailey et al., 2000).

Historical Context & Evolution

Naringenin’s original role was as a food constituent, not a medicine. It and its sugar-bound form naringin give grapefruit its bitterness, and naringin has long been used as a food bittering agent. Citrus flavonoids entered nutrition science in the 1930s, when they were briefly classed as “vitamin P” for effects on small blood vessels, a label later dropped when no deficiency disease could be shown.

Naringenin gained wider attention after grapefruit juice was found to raise blood levels of certain drugs. Naringin was the first suspect, but later human work showed that furanocoumarins (other grapefruit compounds) drive most of that interaction, while naringenin produces only weak, competitive enzyme inhibition (Bailey et al., 2000). Research then shifted to metabolic, liver, and anti-inflammatory uses, and a human safety trial confirmed oral doses up to 900 mg were well tolerated (Rebello et al., 2020).

Consideration for hair began with cell studies. In 2017, researchers at a hair-care company’s laboratory reported that naringenin increased growth of human hair-follicle cells and growth-signal release (Madaan et al., 2017). In 2023, an academic group found that a 0.5% scalp-type solution increased hair regrowth and follicle numbers in mice, though less than minoxidil (Khayoon et al., 2023). In 2026, topical naringin matched or exceeded minoxidil in mice (Zheng et al., 2026). These findings remain preliminary rather than settled; the transition from dietary compound to topical hair candidate has not yet been tested in human trials.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: no human trial of topical naringenin has measured hair outcomes; the evidence consists of one rodent study and cell-culture assays.

Medium 🟩 🟩

No benefit reaches Medium: no single human trial or observational dataset has measured hair regrowth, density, or shedding with naringenin applied to the scalp.

Low 🟩

Speculative 🟨

Hair regrowth and follicle density

Topical 0.5% naringenin raised mouse regrowth and follicle count, without adding follicles beyond minoxidil when combined (Khayoon et al., 2023), and boosted cultured human follicle-cell growth (Madaan et al., 2017). Animal and cell data only.

Hair pigment support ⭕️ Not Central to Hair Regrowth

Naringenin increased melanin and tyrosinase (the pigment-making enzyme) in mouse pigment cells (Ohguchi et al., 2006). This bears on graying, not regrowth. Basis is cell-culture data only.

Scalp inflammation and sun-damage protection ⭕️ Not Central to Hair Regrowth

A naringenin formulation reduced ultraviolet-B skin swelling and cytokines in hairless mice (Martinez et al., 2016). This bears on scalp-skin health, not regrowth. Basis is animal data only.

Benefit-Modifying Factors

  • Genetic polymorphisms: Androgen-receptor gene variants set follicle sensitivity to male hormones and drive pattern hair loss. Because naringenin has no antiandrogen action, benefit is expected to be smallest where hormone-driven miniaturization (progressive follicle shrinking) dominates, such as early-onset, strongly familial loss.
  • Baseline biomarkers: Low ferritin (iron-storage protein), low vitamin D, or abnormal thyroid function can cause shedding that no topical agent reverses. Correcting these first allows any naringenin effect to be judged; no biomarker predicts naringenin response.
  • Sex: Female pattern hair loss depends less on androgens than male pattern loss, so a non-hormonal agent may fit women’s hair loss relatively better; no sex-specific naringenin data exist.
  • Pre-existing conditions: Seborrheic dermatitis (flaky, inflamed scalp) or psoriasis (scaly immune-driven skin disease) raise naringenin penetration about 13-fold (Alalaiwe et al., 2020), possibly increasing both effect and irritation. Scarring alopecia (permanent follicle destruction) and alopecia areata (immune-driven patchy loss) are untested.
  • Age: Older adults have more fully miniaturized or lost follicles; agents acting on living follicles regrow less where follicles are gone. No age-stratified naringenin data exist.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: no human trial of topical naringenin has recorded adverse events; the human harm data are patch tests of minoxidil vehicles and one oral single-dose trial.

Medium 🟥 🟥

No risk reaches Medium: the only controlled human safety trial of naringenin used oral, not scalp, administration, so its adverse-event data are indirect.

Low 🟥

Scalp contact dermatitis from the solvent vehicle

Naringenin barely dissolves in water, so scalp solutions rely on ethanol or propylene glycol, which can cause irritant or allergic contact dermatitis (itchy, scaly rash). Human patch-test data (skin allergy testing) come from minoxidil solutions (Kiratiwongwan et al., 2025; Friedman et al., 2002). Reactions resolve after stopping.

Magnitude: Propylene glycol caused 17.1% of 99 patch-test-confirmed allergic reactions to minoxidil solutions; no rate exists for naringenin preparations.

Systemic adverse effects after absorption

Scalp application may deliver small amounts into the blood. In a placebo-controlled trial, single oral doses of 150–900 mg produced no relevant adverse events or blood-safety changes in 18 adults (Rebello et al., 2020). The data are oral and single-dose, hence indirect.

Magnitude: No relevant adverse events at single oral doses up to 900 mg, well above plausible scalp absorption; repeated and topical exposure remain unquantified.

Speculative 🟨

Drug interactions through CYP3A4 inhibition

Naringenin inhibited CYP3A4 activity by 39% at high concentrations in human liver tissue (Ho et al., 2001). Scalp absorption is likely too low to matter. Basis is mechanistic only.

Reduced follicle blood-vessel growth ⚠️ Conflicted

Naringenin blocked VEGF-driven vessel growth (Pafumi et al., 2017) yet raised skin VEGF (Khayoon et al., 2023); one measured vessel response, the other VEGF levels. Animal data only. Net reading: scalp direction is unknown.

Estrogen-pathway disruption

Naringenin inhibited aromatase (the enzyme converting androgens to estrogens) in a cell-free assay (Edmunds et al., 2005), but oral dosing showed no hormonal effect in rats (Saarinen et al., 2001). Basis is mechanistic only.

Risk-Modifying Factors

  • Genetic polymorphisms: No variant is known to change topical risk. Reduced-function UGT1A1 (the enzyme variant behind Gilbert syndrome, a benign bilirubin-clearance disorder) slows glucuronide clearance and could matter only if oral naringenin is added.
  • Baseline biomarkers: No biomarker predicts scalp reactions. Elevated ALT or AST (liver-injury markers) warrant caution only when topical use is combined with oral naringenin.
  • Sex: Pregnant or breastfeeding women lack safety data, and dietary naringenin passes into breast milk. No other sex differences in skin reactions are documented.
  • Pre-existing conditions: Eczema, psoriasis, or broken skin raise penetration and irritation; known propylene glycol or citrus allergy raises dermatitis risk.
  • Age: Older adults have thinner, drier scalp skin that tolerates alcohol vehicles less well, and more often take medications metabolized by CYP3A4.

Key Interactions & Contraindications

  • Prescription CYP3A4 substrates (felodipine, cyclosporine, tacrolimus, simvastatin): Monitor. Topical naringenin is unlikely to raise drug levels, but adding oral naringenin or grapefruit extracts could increase exposure and toxicity (low blood pressure, kidney injury, muscle damage). Mitigation: keeping naringenin topical-only avoids this.
  • Topical minoxidil: Caution. Combined alcohol and propylene glycol vehicles add itching, scaling, and dermatitis; added regrowth is unproven. Mitigation: separate application times (morning versus evening) or propylene-glycol-free vehicles.
  • Topical retinoids (vitamin A–derived skin drugs such as tretinoin): Caution. Both increase skin penetration and dryness, raising irritation and dermatitis risk. Mitigation: alternate-evening application, stopping if redness persists beyond 48 hours.
  • Over-the-counter ketoconazole shampoo and salicylic acid scalp products: Monitor. Drying or peeling agents add irritation; ketoconazole’s anti-inflammatory action may be complementary. Mitigation: several hours’ separation, and alternate days if redness appears.
  • Oral naringenin, naringin, or grapefruit-extract supplements: Caution. Cumulative systemic exposure adds CYP3A4 inhibition, raising levels of dependent drugs. Mitigation: no oral naringenin products alongside CYP3A4-dependent medications.
  • Additive topical botanicals (rosemary oil, caffeine solutions, green tea extract): Monitor. Overlapping antioxidant and circulation effects may be additive; stacked solvents increase irritation. Mitigation: introducing one product at a time, two weeks apart.
  • Microneedling and scalp procedures: Caution. Needle channels raise penetration and inflammation, risking irritation or infection. Mitigation: withholding naringenin for 24–48 hours after the procedure.

Populations who should avoid Topical Naringenin:

  • Pregnant or breastfeeding women (no safety data)
  • People with a positive patch test to propylene glycol or to citrus flavonoids
  • People with active scalp dermatitis, psoriasis flares, or open wounds, or within 48 hours of microneedling
  • Children and adolescents under 18 years (no data)
  • People with sudden or patchy hair loss not yet diagnosed, where scarring alopecia must first be excluded

Risk Mitigation Strategies

  • Patch test first: a small amount applied behind the ear once daily for 48–72 hours, stopping if redness or itching appears, prevents widespread contact dermatitis.
  • Propylene-glycol-free vehicle: dissolving naringenin in ethanol–water (about 70:30) or glycerin-based solutions avoids the propylene glycol allergy seen in 17.1% of confirmed minoxidil-solution reactions.
  • Conservative concentration: 0.5% (5 mg/mL), the only tested strength, once daily limits irritation; higher strengths add irritation risk without evidence of more regrowth.
  • Intact skin only: pausing application for 24–48 hours after microneedling and during dermatitis flares prevents the roughly 13-fold penetration increase and irritation through a damaged barrier.
  • Topical-only when on CYP3A4 drugs: excluding oral naringenin and grapefruit extracts during felodipine, cyclosporine, tacrolimus, or simvastatin therapy prevents raised drug levels and toxicity.
  • Proven therapy continued: keeping established treatments such as minoxidil or finasteride during a naringenin trial prevents progression and shedding from an unproven substitution.
  • Photograph and stop rule: standardized photographs at baseline and every 3 months, with discontinuation after 6 months without visible benefit, limit ongoing irritation exposure.

Therapeutic Protocol

  • Tested regimen: 0.5% naringenin dissolved in ethanol, applied once daily to the treated area for 21 days in mice (Khayoon et al., 2023); no human protocol has been tested.
  • Human translation (untested): by analogy with minoxidil solutions, about 1 mL of 0.5% solution (5 mg naringenin) applied to dry thinning scalp once daily; an extrapolation, not a validated dose.
  • Alternative – add-on to minoxidil: 0.5% naringenin alongside 5% minoxidil, the combination tested in the same mouse study (Khayoon et al., 2023); regrowth beyond minoxidil alone was not shown.
  • Alternative – naringin solution: 4% naringin, the sugar-bound precursor, outperformed 5% minoxidil in mice (Zheng et al., 2026); human data are absent.
  • Alternative – drug-first approach: dermatology practice and commentators such as Derek of More Plates More Dates favor minoxidil plus 5-alpha-reductase inhibitors (drugs blocking DHT formation), supported by trials (Gupta et al., 2025).
  • Origin of the approach: no clinic or recognized expert has popularized topical naringenin; the tested regimen comes from the University of Kufa pharmacology group (Khayoon, Hadi) and circulates in self-experimentation communities.
  • Time of day: evening application to dry scalp allows several hours of contact before washing; no time-of-day data exist.
  • Half-life: oral naringenin’s blood half-life is about 2.65–3.0 hours (Rebello et al., 2020); residence in skin after topical use is unmeasured.
  • Single versus split dose: once daily is the only tested schedule; twice-daily application is untested and doubles solvent exposure.
  • Genetic polymorphisms: no pharmacogenetic data exist; strongly androgen-driven patterns (early onset, strong family history) are less likely to respond to an agent without antiandrogen action.
  • Sex: no sex-specific dosing exists; use during pregnancy and breastfeeding is unstudied, and women with female pattern loss may find a non-hormonal option relatively suitable.
  • Age: older adults with extensive follicle loss and thinner skin may favor lower-alcohol vehicles; no age-specific dosing exists.
  • Baseline biomarkers: correcting low ferritin, low vitamin D, or thyroid abnormalities before starting prevents deficiency-driven shedding from masking any topical effect.
  • Pre-existing conditions: treating seborrheic dermatitis or psoriasis first matters, since inflamed skin absorbs more naringenin and irritates more easily.

Discontinuation & Cycling

  • Duration: intended as ongoing use like other topical hair-growth agents; a defined 6-month trial with photographs determines whether continuing is worthwhile.
  • Withdrawal effects: none reported for naringenin; any regrowth, if real, would be expected to recede over months after stopping, as occurs with minoxidil.
  • Tapering: not required for naringenin itself; when used alongside minoxidil, the two can be stopped separately, since abrupt minoxidil withdrawal triggers shedding that could be misattributed.
  • Cycling: no evidence supports cycling to maintain efficacy; the long hair-growth cycle favors continuous application.

Sourcing and Quality

  • Compound identity: naringenin (the free compound) differs from naringin (the sugar-bound form); products labeled “grapefruit extract” often contain mainly naringin, so the certificate of analysis should state naringenin content.
  • Purity and third-party testing: quality markers are 98% or higher purity by HPLC (high-performance liquid chromatography, a laboratory purity test) and independent testing for heavy metals and residual solvents.
  • Stereochemistry: most commercial naringenin is racemic (an equal mix of mirror-image forms), while the natural form is (2S)-naringenin; no hair data compare the forms.
  • Formulation: naringenin dissolves poorly in water; elastic liposomes increased skin deposition 7.3–11.8-fold over aqueous solution (Tsai et al., 2015), and ethanol solutions were used in the mouse study.
  • Suppliers: no finished hair product with a disclosed, tested naringenin concentration was identified; research-grade powder is available from chemical suppliers such as Sigma-Aldrich, and compounding pharmacies can prepare scalp solutions.
  • Storage: amber bottles protect against light and heat; refrigerated liposomal preparations retained 98.9% of naringenin after 3 months (Tsai et al., 2015).

Practical Considerations

  • Time to effect: mice showed regrowth within 21 days (Khayoon et al., 2023), but human hair cycles are far slower; established topicals need 3–6 months for visible change, making 6 months the minimum fair trial.
  • Common pitfalls: confusing naringin with naringenin; trying to dissolve it in water; expecting grapefruit intake to reach the scalp; abandoning proven therapy; judging results without baseline photographs.
  • Regulatory status: naringenin is sold as a dietary supplement and cosmetic ingredient; it is not approved by the FDA (US Food and Drug Administration) or any regulator for hair loss.
  • Cost and payer incentives: bulk powder is inexpensive; the main barrier is self-compounding. Neither naringenin nor over-the-counter minoxidil is reimbursed, so no payer incentive shapes this evidence.

Interaction with Foundational Habits

  • Sleep: None known directly. Topical naringenin has no documented effect on sleep. Poor sleep and circadian (body-clock) disruption are associated with increased shedding, so consistent sleep matters when judging response; evening application before bed maximizes contact time.
  • Nutrition: Indirect. Adequate protein, iron, zinc, and vitamin D support follicle growth, and deficiencies cause shedding naringenin cannot offset. Dietary citrus supplies naringin, but oral intake is not shown to reach scalp concentrations relevant to hair.
  • Exercise: Indirect. Exercise supports circulation, but heavy sweating can dilute or wash off the solution; applying after the post-workout shower preserves contact time. No study links exercise to naringenin response.
  • Stress management: Indirect. Acute stress can trigger telogen effluvium (widespread shedding two to three months after a stressor), which naringenin is not shown to prevent; no cortisol effect is documented for topical use, so stress control stabilizes the baseline for assessment.

Monitoring Protocol & Defining Success

Baseline: Before starting, standardized scalp photographs (same lighting, part line, and angles) and a trichoscopy hair count (magnified scalp imaging) establish a reference point. Blood tests screen for common, correctable causes of shedding (iron stores, thyroid function, vitamin D, zinc) so that any change can be attributed correctly. A 48–72-hour patch test checks for vehicle reactions.

Ongoing: Photographs and hair counts are repeated at 3 months and 6 months, then every 6–12 months if use continues. Blood tests are repeated at 3 months only if baseline values were abnormal and have been corrected. Liver enzymes are added only if oral naringenin is also used. Success is defined as a measurable density increase or reduced shedding by 6 months without scalp irritation.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Ferritin 70–150 ng/mL Iron reserve for follicles Conventional range about 15–150 ng/mL (women) and 30–400 ng/mL (men); pair with CBC (complete blood count); morning draw preferred
TSH 0.5–2.5 mIU/L Thyroid-driven shedding TSH (thyroid-stimulating hormone); conventional range 0.4–4.5 mIU/L; pair with free T4 (thyroxine, the main thyroid hormone); morning draw
25-hydroxyvitamin D 40–60 ng/mL Deficiency linked to shedding Conventional sufficiency 30 ng/mL or higher; no fasting required
Zinc (serum) 90–120 µg/dL Deficiency causes shedding Conventional range about 60–120 µg/dL; morning fasting draw, since levels fall after meals
Hair density (trichoscopy) No established target; track change from own baseline Objective regrowth measure Same clinic, device, and marked scalp site each time; reported as hairs/cm²
ALT and AST Below 25 U/L each Liver safety if oral use added ALT (alanine aminotransferase) and AST (aspartate aminotransferase) are liver-injury markers; conventional upper limit about 40 U/L; only needed with oral naringenin

Qualitative markers:

  • Shedding: daily hair fall during washing or brushing, and pull-test counts (hairs released by a gentle tug)
  • Scalp comfort: itching, redness, scaling, or burning after application
  • Hair quality: strand thickness, texture, and visible coverage in photographs
  • Styling and confidence: perceived fullness and ease of styling

Emerging Research

  • No registered hair trials: As of September 2026, ClinicalTrials.gov lists no trial of topical naringenin for hair. The only ongoing naringenin trial is oral: NCT06612762 randomizes 70 fracture patients to 500 mg then 250 mg daily versus placebo, with inflammatory markers as primary endpoint.
  • Safety groundwork: the completed trial NCT03582553, an early-phase single-ascending-dose study in 18 adults, supplies the human safety data (Rebello et al., 2020); a scalp-exposure study would be the logical next step for health-focused users.
  • Polyphenol class trials: a meta-analysis of 32 randomized trials found polyphenol interventions improved hair density (El Ammari et al., 2026), strengthening the class rationale; only a naringenin-specific trial can show whether this compound shares the effect.
  • Precursor comparison: naringin at 4% outperformed 5% minoxidil in mice (Zheng et al., 2026); comparing naringin with naringenin directly could clarify which form better reaches follicles.
  • Delivery systems: elastic liposomes and nanoparticle creams raise skin retention (Tsai et al., 2015; Joshi et al., 2018); follicle-targeted formulations could change the effective dose.
  • Findings that could weaken the case: naringenin’s anti-blood-vessel action (Pafumi et al., 2017) and absent antiandrogen activity (Zierau et al., 2003) predict limited benefit in hormone-driven loss; human hair-count trials would test this directly.
  • Gray hair: a 2025 review lists naringenin among plant compounds that increase pigment production (Wei et al., 2025), pointing to research on combined regrowth and repigmentation.

Conclusion

Naringenin is a natural citrus compound that, applied to the scalp, is proposed to support hair regrowth by strengthening growth signals in hair-forming cells and shielding them from chemical stress. For health-focused adults already willing to keep a daily scalp routine, it is inexpensive and appears gentle, though no ready-made hair product exists, so solutions must be mixed at home or by a pharmacy.

The evidence, however, is at the earliest stage. Support comes from laboratory work on human scalp cells and a small number of animal studies, one of them using a closely related citrus compound; no study has yet measured hair regrowth in people. Some laboratory findings point the other way, suggesting it may slow blood-vessel growth, and it does not act on the hormone behind most pattern hair loss. The cell research came from the laboratory of a company that sells hair-care products, which has a financial interest in a favorable result.

The known risks are mild and come mainly from the liquids used to dissolve it, which can irritate the scalp or cause an allergic rash. Naringenin taken orally has a good short-term safety record, and the small amounts absorbed through skin make medicine interactions unlikely.

Overall, scalp-applied naringenin is an unproven, low-risk, experimental option. Its value next to established hair-loss treatments is uncertain, and whether it regrows human hair at all remains unknown.

Top - Benefits - Risks - Protocol